5 mg Pulver zur Herstellung einer Injektionslösung

DRUG2 trials

Sponsors

Alexion Pharmaceuticals Inc., University Medical Center Hamburg-Eppendorf

Conditions

HYPOPHOSPHATASIAmultiple myeloma

Phase 3

Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy

CompletedCTIS2024-510590-14-00

University Medical Center Hamburg-Eppendorfmultiple myeloma

Start: 2023-03-03End: 2025-01-30Target: 400Updated: 2025-02-05

Phase 4

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

CompletedCTIS2022-502793-17-00

Alexion Pharmaceuticals Inc.HYPOPHOSPHATASIA

End: 2025-08-08Target: 1Updated: 2024-09-19